Determining the stage in Chlamydia development targeted by our best antichlamydials.

The data underlying Fig 5. (A) Effect of top compounds on EB formation in HeLa cells infected with CTL2-GFP. Data are displayed in Fig 5B. (B) Growth inhibition after addition of top compounds at different points in the developmental cycle, tested in HeLa cells infected with CTL2-GFP, as measured at 48 hpi by bulk GFP fluorescence. Data are displayed in Fig 5C. (C) Antichlamydial activity of our best compounds in A2EN cells (wild-type or mutant as indicated) infected with CTL2-GFP, as measured at 28.5 hpi by bulk GFP fluorescence. Data are displayed in Fig 5D. (D) LC3 lipidation and STING phosphorylation after compound exposure in uninfected A2EN cells and cells infected with CTL2. Data are displayed in Fig 5E and 5F. (XLSX)